Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | KMO | O15229 | 1/20 | 0.55 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 2/20 | 0.53 |
| ▸ | SLC9A1 | P19634 | 4/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.49 |
| ▸ | DAO | P14920 | 1/20 | 0.47 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29117331 | 0.98 | CYP1A2 (0.55) | CYP1A2KMOP2RX7RECQLSLC9A1 | |
| SCHEMBL20083775 | 0.98 | CYP1A2 (0.55) | CYP1A2KMOP2RX7RECQLSLC9A1 | |
| SCHEMBL1326630 | 0.95 | CYP1A2 (0.58) | CYP1A2KMOP2RX7RECQLSLC9A1 | |
| SCHEMBL5565705 | 0.87 | CYP1A2 (0.62) | CYP1A2KMOP2RX7RECQLSLC9A1 | |
| SCHEMBL29487638 | 0.87 | CYP1A2 (0.62) | CYP1A2KMOP2RX7RECQLSLC9A1 | |
| SCHEMBL31301070 | 0.83 | CYP1A2 (0.57) | CYP1A2KMOP2RX7RECQLPOLB | |
| SCHEMBL5365409 | 0.83 | KMO (0.59) | CYP1A2KMOP2RX7RECQLPOLB | |
| SCHEMBL319515 | 0.82 | RECQL (0.61) | CYP1A2KMOP2RX7RECQLSLC9A1 | |
| SCHEMBL31429798 | 0.81 | CYP1A2 (0.55) | CYP1A2KMOP2RX7RECQLPOLB | |
| SCHEMBL29351604 | 0.81 | CYP1A2 (0.51) | CYP1A2KMOP2RX7RECQLPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3193610-A1 | SELECTIVE NAV1.7 INHIBITORS FOR THE TREATMENT OF DIABETES | Chromocell Corporation (US) | 2017-07-26 | — | — | EP | claimed |
| WO-2016040315-A1 | SELECTIVE NAV1.7 INHIBITORS FOR THE TREATMENT OF DIABETES | CHROMOCELL CORPORATION (US) | 2016-03-17 | — | — | WO | claimed |
| US-20080033184-A1 | INTERMEDIATES AND METHODS FOR SEROTONERGIC AGONIST SYNTHESIS | ALCON MANUFACTURING, LTD. (US) | 2008-02-07 | — | — | US | claimed |
| WO-2008016993-A1 | INTERMEDIATES AND METHODS FOR SEROTONERGIC AGONIST SYNTHESIS | ALCON RESEARCH, LTD. (US) | 2008-02-07 | — | — | WO | claimed |
| JP-5246998-A | — | — | None | — | — | JP | disclosed |
| US-11958873-B2 | Proteasome activity enhancing compounds | Kineta, Inc. (US) | 2024-04-16 | — | — | US | disclosed |
| US-20230242557-A9 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | Kineta, Inc. | 2023-08-03 | — | — | US | disclosed |
| US-11242361-B2 | Proteasome activity enhancing compounds | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| CN-108191764-B | Synthesis method of 1, 3-diaryl-1, 5,6, 7-tetrahydroindazole derivative | 扬州大学 | 2021-04-16 | — | — | CN | disclosed |
| US-20200308198-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. | 2020-10-01 | — | — | US | disclosed |
| US-20180282352-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. | 2018-10-04 | — | — | US | disclosed |
| US-9850262-B2 | Proteasome activity enhancing compounds | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| EP-0630367-A1 | NOVEL ARYLINDAZOLES AND THEIR USE AS HERBICIDES | ZENECA LIMITED (GB) | 1994-12-28 | — | — | EP | disclosed |
| US-5266556-A | Herbicides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1993-11-30 | — | — | US | disclosed |
| US-5266556-A | Herbicides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1993-11-30 | — | — | US | disclosed |
| JP-H05246998-A | ARYLINDAZOLE DERIVATIVE AND HERBICIDE CONTAINING THE DERIVATIVE AS ACTIVE COMPONENT | SUMITOMO CHEM CO LTD | 1993-09-24 | — | — | JP | disclosed |
| WO-1993018008-A1 | NOVEL ARYLINDAZOLES AND THEIR USE AS HERBICIDES | ZENECA LIMITED (GB) | 1993-09-16 | — | — | WO | disclosed |
| EP-0544218-A1 | Arylindazole derivatives and their use | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1993-06-02 | — | — | EP | disclosed |
| EP-0544218-A1 | Arylindazole derivatives and their use | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1993-06-02 | — | — | EP | disclosed |
| US-4937247-A | EMETIC AGENTS, ANALGESICS | BEECHAM GROUP P.L.C. (GB) | 1990-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242557-A9 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSMB1, PSMC1 | CYP1A2 4052/4885KMO 3631/4885P2RX7 3852/4885 |
| US-20180282352-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSMB1, PSMC1 | CYP1A2 4052/4885KMO 3631/4885P2RX7 3852/4885 |
| US-11242361-B2 | Proteasome activity enhancing compounds | PSMG3, PSMB1, PSMC1 | CYP1A2 4052/4885KMO 3631/4885P2RX7 3852/4885 |
| US-20200308198-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSMB1, PSMC1 | CYP1A2 4052/4885KMO 3631/4885P2RX7 3852/4885 |
| US-20080033184-A1 | INTERMEDIATES AND METHODS FOR SEROTONERGIC AGONIST SYNTHESIS | HTR3B, HTR3A, HTR4 | CYP1A2 152/4885KMO 86/4885P2RX7 251/4885 |
| US-11958873-B2 | Proteasome activity enhancing compounds | PSMG3, PSMB1, PSMC1 | CYP1A2 4052/4885KMO 3631/4885P2RX7 3852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.